Genentech's Polivy Plus R-CHP Shows Prolonged Survival In Lymphoma

 

• Genentech, a member of Roche Holdings AG (OTC: RHHBY), announced that the pivotal Phase 3 POLARIX trial met its primary endpoint in people with previously untreated diffuse large B-cell lymphoma (DLBCL).
• The trial investigated Polivy (polatuzumab vedotin) in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) versus Rituxan plus cyclophosphamide, doxorubicin, vincristine, and prednisone or R-CHOP.
• The trial demonstrated significantly improved and clinically meaningful progression-free survival. The phase 3 study showed Polivy Plus R-CHP is the first regimen in 20 years to significantly improve outcomes in a previously untreated aggressive form of lymphoma compared to standard of care.

https://m.benzinga.com/article/22395731